NYSE: PFEPfizer Inc Stock
$43.95+0.03 (+0.07%)
Updated Sep 22, 2021
PFE Price
$43.95
Fair Value Price
N/A
Market Cap
$246.41B
52 Week Low
$33.36
52 Week High
$51.86
P/E
18.62x
P/B
3.52x
P/S
4.31x
PEG
1.67x
Dividend Yield
3.53%
Revenue
$51.64B
Earnings
$13.23B
Gross Margin
70.4%
Operating Margin
28.19%
Profit Margin
25.6%
Debt to Equity
1.42
Operating Cash Flow
$24B
Beta
0.69
Next Earnings
Oct 25, 2021
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
High
Medium
Low
51
Industry average
Reasons for this score
PFE ($43.95) is trading below its intrinsic value of $127.45, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
PFE is good value based on its earnings relative to its share price (18.62x), compared to the US market average -10.34x)
Valuation
PFE is good value based on its earnings relative to its share price (18.62x), compared to the US Drug Manufacturers - General industry average (21.92x)
Valuation
PFE News
Valuation
PFE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
18.62x
Industry
21.92x
Market
-10.34x
PFE is good value based on its earnings relative to its share price (18.62x), compared to the US market average -10.34x)
Valuation
PFE is good value based on its earnings relative to its share price (18.62x), compared to the US Drug Manufacturers - General industry average (21.92x)
Valuation
PFE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.52x
Industry
5.12x
PFE is good value based on its book value relative to its share price (3.52x), compared to the US Drug Manufacturers - General industry average (5.12x)
Valuation
PFE price to earnings growth (PEG)
For valuing profitable companies with growth potential
PFE is poor value relative to its rate of earnings growth, measured by PEG ratio (1.67x)
Valuation
PFE's financial health
Profit margin
Revenue
$19.0B
Net Income
$5.6B
Profit Margin
29.3%
PFE's Earnings (EBIT) of $14.56B can safely cover interest payments on company debt ($39.24B)
Financials
PFE's profit margin has decreased (-15.2%) in the last year from (40.8%) to (25.6%)
Financials
Assets to liabilities
Assets
$169.9B
Liabilities
$99.6B
Debt to equity
0.56
PFE's short-term assets ($48.81B) exceed its short-term liabilities ($35.66B)
Financials
PFE's long-term liabilities ($63.94B) exceed its short-term assets ($48.81B)
Financials
PFE's debt relative to shareholder equity (1.42) has decreased or remained constant compared to 5 years ago (1.71)
Financials
PFE's debt to equity ratio (1.42) is considered high
Financials
Cash flow
Operating
$11.3B
Investing
-$8.1B
Financing
-$2.6B
PFE's operating cash flow ($23.55B) is sufficient to service the company's debt ($39.24B)
Financials
Pfizer Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.